Lantheus Holdings discloses litigation, Morgan Stanley valuation ranges ahead of stockholder vote
Lantheus Holdings disclosed litigation and updated Morgan Stanley valuation analyses ahead of its October 14 stockholder meeting. Three complaints allege omissions in proxy statements, seeking to block the merger. The company provided supplemental disclosures but denies any deficiencies. Morgan Stanley's updated valuation ranges: DCF $88.10–$118.60/sh, comparable-company EV/EBITDA $63.85–$84.20/sh, analyst targets $98–$129.
How this was made
The 30-second read
Why it matters
The new litigation exposure and valuation updates introduce fresh downside risk, prompting traders to reassess LNTH's near‑term price target.
Market read
First‑report disclosure of shareholder litigation and revised valuation ranges creates a material news event for LNTH, likely influencing short‑term price action.
What to watch
The filing does not disclose the size of potential damages or the likelihood of settlement, which could moderate price reaction.
Background
Lantheus Holdings filed an 8‑K on Oct 2, 2026, detailing three shareholder complaints alleging proxy omissions and sixteen demand letters seeking more disclosures, while also providing updated Morgan Stanley DCF and comparable valuation ranges.
Ticker impact
Lantheus disclosed new shareholder litigation and updated Morgan Stanley valuation ranges in an 8‑K filing ahead of its special meeting.
downside pressure as investors price in litigation risk and the lower end of the valuation range
The filing is the first public disclosure of the lawsuits and revised valuation ranges, which typically depress share price until resolved.
Market effects
Potential ripple to other diagnostic imaging firms as litigation may raise sector risk perception.
Limited to U.S. markets where LNTH trades; no broader regional effect.
Minimal global impact beyond investors tracking U.S. biotech stocks.
Counterpoint
If the lawsuits are dismissed, the valuation range could be seen as a floor, offering upside potential.
Key entities
- companyLantheus Holdings
U.S. diagnostic imaging and radiopharmaceuticals company (ticker LNTH).
- analystMorgan Stanley
Provided updated valuation ranges for LNTH.
